Enhanced Safety Profile of Ocrelizumab Over Rituximab in Multiple Sclerosis Treatment

Authors
Category Primary study
ConferenceAnnual Meeting of the American Academy of Neurology, AAN 2025
Year 2025
This article has no abstract
Epistemonikos ID: a2418f24af71e12a6d1b06271ffe942828d1e342
First added on: Sep 12, 2025